---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134840"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:23:17.255281+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics treats first SLE patient with FT819; advances autoimmune pipeline

## Summary
- First SLE patient dosed in Phase 1 autoimmunity study of FT819 (CD19 CAR T); discharged after 3 days with no notable AEs.
- FT819 translational data: rapid deep B-cell depletion, tissue trafficking, plasma cell depletion; fludarabine not required in some cases.
- FT522 (CAR NK) initial observations: rapid sustained B-cell depletion and enhanced persistence vs FT596 in first two BCL patients.
- Company completed dose escalation in FT819 BCM study; will focus FT819 solely on autoimmunity; FT522 IND for autoimmune diseases expected mid-2024.
- FT819 safety in BCM study: no DLTs, ICANS, or GvHD; low-grade CRS in 14% of patients; no study discontinuations or deaths.

## SEC filing metadata
- accession: 0001193125-24-134840
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524134840/0001193125-24-134840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524134840/d675282d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134840
- JSON: https://secwatch.observer/filing/0001193125-24-134840.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.